Pipeline Review for Endometriosis - H1 2020 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Endometriosis - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis - Pipeline Review, H1 2020, provides an overview of the Endometriosis (Women's Health) pipeline landscape.

Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. Risk factors age, uterine abnormalities, history of pelvic infection and family history. Treatment includes NSAIDs, birth control pills and progestins.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Endometriosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Endometriosis (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Endometriosis (Women's Health) pipeline guide also reviews key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 11, 12, 1, 16, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 2 molecules, respectively.

Endometriosis (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Endometriosis (Women's Health).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Endometriosis (Women's Health) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Endometriosis - Overview
• Endometriosis - Therapeutics Development
• Endometriosis - Therapeutics Assessment
• Endometriosis - Companies Involved in Therapeutics Development
• Endometriosis - Drug Profiles
• Endometriosis - Dormant Projects
• Endometriosis - Discontinued Products
• Endometriosis - Product Development Milestones
• Appendix

Companies Mentioned

• Adynxx Inc
• Aptorum Group Ltd
• ARTham Therapeutics Inc
• Auritec Pharmaceuticals Inc
• Bayer AG
• Bol Pharma
• Chugai Pharmaceutical Co Ltd
• Context Therapeutics LLC
• Daewoong Pharmaceutical Co Ltd
• ElexoPharm GmbH
• Enteris BioPharma Inc
• Eurofarma Laboratorios SA
• Evestra Inc
• Evotec SE
• FemmePharma Global Healthcare Inc
• Forendo Pharma Oy
• GeneScience Pharmaceuticals Co Ltd
• Immunitor Inc
• Jiangsu Hengrui Medicine Co Ltd
• Kissei Pharmaceutical Co Ltd
• Livzon Pharmaceutical Group Co Ltd
• Luye Pharma Group Ltd
• Mitsubishi Tanabe Pharma Corp
• Navad Life Sciences Pte Ltd
• Nippon Shinyaku Co Ltd
• Philogen SpA
• Predictive Therapeutics LLC
• PregLem SA
• SYNG Pharmaceuticals Inc
• Takeda Pharmaceutical Co Ltd
• Temple Therapeutics BV
• TiumBio Co Ltd
• Union Therapeutics AS
• ValiRx Plc
• Viramal Ltd
• Xbrane Biopharma AB

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/f0tnne